"RIV/00669806:_____/11:10209994" . "Stelljes, Matthias" . "Finke, Juergen" . "[0746C4CFC5D9]" . "23"^^ . . . . "Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius"@en . "Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P =.47, and HR = 0.68, P =.18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P =.39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P <.0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity."@en . "I, V" . "Koza, Vladim\u00EDr" . "Bornhaeuser, Martin" . "190343" . "Einsele, Hermann" . "Soci\u00E9, G\u00E9rard" . "Zander, Axel R." . . . "Linkesch, Werner" . "Heim, Dominik A." . "Bertz, Hartmut" . "Maertens, Johan A." . "Schmoor, Claudia" . "Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius"@en . "Kolbe, Karin" . . "10.1182/blood-2011-01-329821" . "Blood" . "8"^^ . "Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius" . "Volin, Liisa" . "Kolb, Hans-Jochem" . . "117" . "Ruutu, Tapani" . "Ottinger, Hellmut D." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Egger, Matthias" . "23" . "1"^^ . . "000291438000041" . "Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius" . "Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P =.47, and HR = 0.68, P =.18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P =.39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P <.0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity." . . . . "Mayer, Ji\u0159\u00ED" . "http://bloodjournal.hematologylibrary.org/content/117/23/6375.long" . . . "RIV/00669806:_____/11:10209994!RIV14-MZ0-00669806" . "Bethge, Wolfgang A." . . "Schwerdtfeger, Rainer" . . "Holler, Ernst" . . . "0006-4971" . "survival; depletion; competing risks; clinical-trials; antithymocyte globulin; follow-up; working group-report; matched unrelated donors; consensus development project; Bone-marrow-transplantation"@en . . . "Grishina, Olga" . . . . .